Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index
Nutrients · 2024
DOI: 10.3390/nu16193344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von I-Hsin Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan. Hauptthemen laut MEDLINE: Obesity, Kidney Transplantation, Body Mass Index. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Chang Gung Memorial Hospital.
Abstract (Originalsprache)
Background/Objectives: Obesity and metabolic conditions increase the risk of metabolic-associated steatotic liver disease (MASLD). This study examined the risk of MASLD in 137 renal transplant recipients (RTRs) from a single-center hospital on the basis of their obesity and metabolic health status.
Methods
Participants were categorized into four groups: metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically abnormal nonobese (MANO), and metabolically abnormal obese (MAO). MASLD was assessed using the hepatic steatosis index (HSI), calculated as 8 × (aspartate aminotransferase/alanine aminotransferase ratio) + body mass index + 2 (if diabetic) + 2 (if woman). The HSI scores were 29.50 ± 4.55, 38.08 ± 5.44, 33.61 ± 5.23, and 39.86 ± 4.13 in the MHNO, MHO, MANO, and MAO groups, respectively (p < 0.05).
Results
Overall, 25.55% of the participants (57.14% men) were classified as having MASLD (HSI > 36). A multivariate-adjusted regression analysis revealed significantly higher HSI scores in the MAO group than in the MHNO group. Both MHO and MANO groups also had significantly higher HSI scores. The odds ratios for more severe MASLD were 2.74 (95% CI: 0.88–8.52) for the MANO group and 74.59 (95% CI: 13.29–418.68) for the MAO group compared with the MHNO group.
Conclusions
These findings suggest that RTRs with obesity have a higher risk of MASLD, but even those with a normal weight and metabolic abnormalities are at increased risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
- Department of Nutrition and Health Sciences, Chinese Culture University, Taipei 111, Taiwan.
- School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110, Taiwan.
- Department of Urology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
- Department of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Department of Business Administration, College of Management, National Changhua University of Education, Changhua 500, Taiwan.
ORCID-Profile: I-Hsin Lin, Tuyen Van Duong, Te-Chih Wong
Förderung
- National Science and Technology Council
- Chang Gung Memorial Hospital
Zitieren
APA
Lin, I. H., Yu, Y. P., Duong, T. V., Nien, S. W., Tseng, I. H., Wu, Y. M., Chiang, Y. J., Chiang, C. Y., Chiu, C. H., Wang, M. H., Yang, N. C., Wu, T. H., & Wong, T. C. (2024). Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index. Nutrients. https://doi.org/10.3390/nu16193344
Vancouver
Lin IH, Yu YP, Duong TV, Nien SW, Tseng IH, Wu YM, et al. Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index. Nutrients. 2024. doi:10.3390/nu16193344
BibTeX
@article{Lin2024,
author = {Lin, I-Hsin and Yu, Yi-Ping and Duong, Tuyen Van and Nien, Shih-Wei and Tseng, I-Hsin and Wu, Yi-Ming and Chiang, Yang-Jen and Chiang, Chia-Yu and Chiu, Chia-Hui and Wang, Ming-Hsu and Yang, Nien-Chieh and Wu, Ta-Ho and Wong, Te-Chih},
title = {Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16193344}
}
EUVIMED